Phase 1 Study of OMN54 – Aneustat

Frontage ran a Phase I Study of OMN54 (Aneustat™) in patients with advanced malignancies.

"*" indicates required fields

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

Comments

This field is for validation purposes and should be left unchanged.

Resources to Consider